Home›Research›Compare›Cagrilintide vs Liraglutide
Peptide ComparisonCagrilintide vs Liraglutide
Both are Metabolic peptides.
Cagrilintide
AM833
Half-life: ~7 days
21 providers listed
Liraglutide
Victoza
Half-life: 13 hours
52 providers listed
Liraglutide is FDA-approved, while Cagrilintide is investigational — the clearest structural difference between them.
Cagrilintide
Half-life
~7 days
Liraglutide
Half-life
13 hours
| Your goal | Better option |
|---|---|
| Further along in FDA review | Liraglutide |
| Less frequent dosing (longer half-life) | Cagrilintide |
| More provider options (21 vs 52) | Liraglutide |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
Cagrilintide
Liraglutide
Cagrilintide
Novel Amylin-Based Therapies for Weight Management in Adults With Overweight or Obesity Without Diabetes: A N…
Efficacy and safety of co-administered cagrilintide and semaglutide versus semaglutide alone in adults with o…
Combination of cagrilintide and semaglutide 2·4 mg for weight management in adults with overweight and obesit…
Cagrilintide 2·4 mg once-weekly subcutaneous injection in adults with overweight or obesity (SCALE-CAGRI): a…
+5 more
Liraglutide
Comparative Effects of Individual Glucagon-Like Peptide-1 Receptor Agonist-Based Medications on Direct Measur…
Semaglutide vs liraglutide for weight loss in adults with overweight or obesity
A randomized, controlled trial of 3.0 mg of liraglutide in weight management
Effects of the GLP-1 receptor agonist liraglutide on bupivacaine-induced sciatic nerve block in a rat model.
+4 more
About Cagrilintide
Long-acting amylin analogue; acts on amylin/calcitonin receptors to prolong satiety; synergistic with semaglutide in CagriSema combination
About Liraglutide
GLP-1 receptor agonist; slows gastric emptying, increases satiety, reduces glucagon secretion
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
Cagrilintide
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Given mechanistic overlap with GLP-1 agonists when used as CagriSema, monitor thyroid C-cell markers (calcitonin), lipase for pancreatitis risk, and a baseline metabolic panel. Amylin-specific monitoring guidance is evolving as Phase 3 data matures; follow prescribing protocol of the co-administered agent.
Liraglutide
Risk of thyroid C-cell tumors (dose- and duration-dependent in rodents; human relevance undetermined).
Source: FDA label
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
Cagrilintide
Liraglutide
Not enough vendor pricing yet.
Where to source these peptides
Cagrilintide
21 listed
Browse directory →
Providers offeringLiraglutide
52 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More Metabolic Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). Cagrilintide vs Liraglutide — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/cagrilintide/liraglutide